Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
MINNEAPOLIS, May 02, 2018 -- Inspire Medical Systems, Inc. (NYSE:INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, announced today the pricing of its initial public offering of 6,750,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Inspire. In addition, Inspire has granted the underwriters a 30-day option to purchase up to 1,012,500 additional shares of its common stock at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on the New York Stock Exchange on May 3, 2018 under the ticker symbol “INSP.” The offering is expected to close on May 7, 2018, subject to customary closing conditions.
BofA Merrill Lynch and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering. Guggenheim Securities, Stifel and Wells Fargo Securities are acting as co-managers for the offering.
A registration statement relating to these securities has been filed and was declared effective by the Securities and Exchange Commission. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting: BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department or via email: [email protected]; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, via telephone: 1-866-471-2526, or via email: [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire Medical Systems’ proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
Inspire Investor and Media Contact
Bob Yedid
LifeSci Advisors
[email protected]
646-597-6989
